☆ 4.7 Review

Biology of GD2 ganglioside: implications for cancer immunotherapy

FRONTIERS IN PHARMACOLOGY (2023)

Related references

Note: Only part of the references are listed.
Article Cell & Tissue Engineering

Generation of anti-GD2 CAR macrophages from human pluripotent stem cells for cancer immunotherapies

Jue Zhang et al.

Summary: In this study, anti-GD2 CAR was integrated into the AAVS1 locus of human pluripotent stem cells using CRISPR-Cas9 gene editing. A serum- and feeder-free differentiation protocol was established to generate CAR macrophages (CAR-Ms) through arterial endothelial-to-hematopoietic transition (EHT). The CAR-Ms produced using this method showed potent cytotoxic activity against GD2-expressing neuroblastoma and melanoma in vitro and neuroblastoma in vivo. This study provides a new platform for efficient generation of off-the-shelf CAR-Ms for antitumor immunotherapy.

STEM CELL REPORTS (2023)

Add to Collection
Article Medicine, General & Internal

GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma

Francesca Del Bufalo et al.

Summary: Immunotherapy with GD2-CAR T cells expressing the inducible caspase 9 suicide gene is a feasible and safe treatment option for high-risk neuroblastoma patients, with a sustained antitumor effect and a significant improvement in overall survival and event-free survival.

NEW ENGLAND JOURNAL OF MEDICINE (2023)

Add to Collection
Article Multidisciplinary Sciences

Extracellular vesicles released from ganglioside GD2-expressing melanoma cells enhance the malignant properties of GD2-negative melanomas

Farhana Yesmin et al.

Summary: Exosomes, small extracellular vesicles, play significant roles in cell-to-cell communication and have been extensively studied for their contents, generation mechanisms, and functions. However, the presence and roles of glycans, especially glycosphingolipids, in exosomes have been rarely reported. This study investigated the expression and function of the cancer-associated ganglioside GD2 in malignant melanomas. The results showed that GD2-expressing melanoma-derived exosomes enhanced the malignant phenotypes of GD2-negative melanomas and induced increased phosphorylation of signaling molecules.

SCIENTIFIC REPORTS (2023)

Add to Collection
Article Immunology

Anti-tumor efficacy of anti-GD2 CAR NK-92 cells in diffuse intrinsic pontine gliomas

Pengcheng Zuo et al.

Summary: This study evaluated the anti-tumor activity and safety of GD2-CAR NK-92 cells for the treatment of DIPG. Results showed that GD2-CAR NK-92 cells effectively killed DIPG cells with high GD2 expression and inhibited tumor growth in vivo, but had limited activity against DIPG cells with low GD2 expression. Further clinical trials are needed to demonstrate the safety and anti-tumor effect of this therapy.

FRONTIERS IN IMMUNOLOGY (2023)

Add to Collection
Article Oncology

GD2 and GD3 gangliosides as diagnostic biomarkers for all stages and subtypes of epithelial ovarian cancer

Alba Galan et al.

Summary: GD2 and GD3 expression is associated with high selectivity and specificity for ovarian cancer, and a diagnostic model combining their quantification in serum has diagnostic power for all subtypes and stages of ovarian cancer, including early stage.

FRONTIERS IN ONCOLOGY (2023)

Add to Collection
Article Pharmacology & Pharmacy

Naxitamab Activity in Neuroblastoma Cells Is Enhanced by Nanofenretinide and Nanospermidine

Lucrezia Galassi et al.

Summary: Neuroblastoma cells highly express the disialoganglioside GD2, and immunotherapy with monoclonal anti-GD2 antibodies has proven efficacy in clinical trials. However, the neuro-toxicity associated with antibody administration limits their therapeutic potential. Nanofenretinide and Nanospermidine increased GD2 expression in neuroblastoma cells and improved the effectiveness of anti-GD2 antibody treatment. This could potentially enable chronic treatments to eradicate minimal residual disease and relapses.

PHARMACEUTICS (2023)

Add to Collection
Article Oncology

Metabolic stress induces GD2+ cancer stem cell-like phenotype in triple-negative breast cancer

Appalaraju Jaggupilli et al.

Summary: This study demonstrates that metabolic stress induces the GD2(+) BCSC phenotype in triple-negative breast cancer (TNBC) and highlights the role of glutamine in this phenotype. Inhibiting glutamine transporters can reduce BCSC characteristics in TNBC cells, suggesting a potential complementary approach to conventional chemotherapy.

BRITISH JOURNAL OF CANCER (2022)

Add to Collection
Review Biochemistry & Molecular Biology

FAK in Cancer: From Mechanisms to Therapeutic Strategies

Hsiang-Hao Chuang et al.

Summary: In this review, the authors summarize the mechanisms of FAK-mediated signaling networks during tumor development and the recent progress of FAK-targeted small-molecule compounds for anticancer activity from preclinical and clinical evidence.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Add to Collection
Article Biochemistry & Molecular Biology

Ganglioside GD2 Enhances the Malignant Phenotypes of Melanoma Cells by Cooperating with Integrins

Farhana Yesmin et al.

Summary: GD2 and integrin beta 1 physically associate in the microdomain of the cell membrane, leading to enhanced malignant phenotypes of melanoma cells.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Add to Collection
Article Oncology

GD2-specific chimeric antigen receptor-modified T cells for the treatment of refractory and/or recurrent neuroblastoma in pediatric patients

Lihua Yu et al.

Summary: The study evaluated the safety and efficacy of using chimeric antigen receptor (CAR) disialoganglioside 2 (GD2)-specific (4SCAR-GD2) T cells for the treatment of refractory and/or recurrent neuroblastoma in pediatric patients. Results showed that 4SCAR-GD2 T-cell therapy demonstrated antitumor effect and manageable toxicities, indicating its potential to benefit children with refractory and/or recurrent NB.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2022)

Add to Collection
Article Oncology

Improved Outcome in Children With Newly Diagnosed High-Risk Neuroblastoma Treated With Chemoimmunotherapy: Updated Results of a Phase II Study Using hu14.18K322A

Wayne L. Furman et al.

Summary: Combining hu14.18K322A with chemotherapy improves early response and outcomes in high-risk neuroblastoma. This treatment is well-tolerated and reduces tumor volume in most patients, leading to improved end-of-induction response rates and encouraging 3-year event-free survival.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection
Article Multidisciplinary Sciences

GD2-CART cell therapy for H3K27M-mutated diffuse midline gliomas

Robbie G. Majzner et al.

Summary: Diffuse intrinsic pontine glioma (DIPG) and other H3K27M-mutated diffuse midline gliomas (DMGs) are lethal pediatric tumors of the central nervous system. GD2-directed chimeric antigen receptor (CAR) T cells show promising preclinical efficacy. Four patients with H3K27M-mutated DIPG or spinal cord DMG were treated with GD2-CAR T cells and showed clinical and radiographic improvement.

NATURE (2022)

Add to Collection
Article Biochemistry & Molecular Biology

Anti-GD2 synergizes with CD47 blockade to mediate tumor eradication

Johanna Theruvath et al.

Summary: The combination of anti-GD2 and CD47 blockade demonstrates robust anti-tumor activity in mouse models, particularly effective against neuroblastoma, osteosarcoma, and small-cell lung cancer.

NATURE MEDICINE (2022)

Add to Collection
Article Oncology

Anti-GD2 CAR MSCs against metastatic Ewing's sarcoma

Giulia Golinelli et al.

Summary: The study demonstrates that bi-functional MSCs expressing TRAIL and GD2 tCAR can effectively target and kill ES tumor cells, showing good efficacy in targeting and eliminating ES in the lungs but not in the liver.

TRANSLATIONAL ONCOLOGY (2022)

Add to Collection
Article Immunology

O-Acetyl-GD2 as a Therapeutic Target for Breast Cancer Stem Cells

Jing-Yan Cheng et al.

Summary: OAcGD2 is a novel marker for breast cancer stem cells, and treatment with anti-OAcGD2 mAb8B6 can suppress tumor growth and reduce cancer metastasis and recurrence.

FRONTIERS IN IMMUNOLOGY (2022)

Add to Collection
Article Chemistry, Multidisciplinary

Analysis and Comparison of Mouse and Human Brain Gangliosides via Two-Stage Matching of MS/MS Spectra

Fanran Huang et al.

Summary: A method for the analysis and comparison of glycosphingolipids (GSLs) in biological issues was developed and verified using human plasma and mouse brains. The method was then used to study the composition and lipid forms of gangliosides in mouse and human brains, revealing differences between the two species. This study demonstrates the broad application of the two-stage MS/MS spectral matching method for studying GSLs and their lipid forms in complex biological samples.

ACS OMEGA (2022)

Add to Collection
Article Oncology

Anti-disialoganglioside antibody internalization by neuroblastoma cells as a mechanism of immunotherapy resistance

Rachelle Tibbetts et al.

Summary: Neuroblastoma cells universally express GD2, but the degree of anti-GD2 antibody internalization varies among different cell lines, and this internalization is inversely correlated with antibody-dependent cellular cytotoxicity.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2022)

Add to Collection
Article Radiology, Nuclear Medicine & Medical Imaging

131I-GD2-ch14.18 Scintigraphy to Evaluate Option for Radioimmunotherapy in Patients with Advanced Tumors

Ying Zhang et al.

Summary: The study evaluated the tumor targeting of 131I-labeled chimeric GD2-antibody in patients with late-stage disease. The results showed that the antibody had high tumor uptake in neuroblastomas and radioimmunotherapy could be an effective treatment option for patients with high uptake.

JOURNAL OF NUCLEAR MEDICINE (2022)

Add to Collection
Article Oncology

TH-MYCN tumors, but not tumor-derived cell lines, are adrenergic lineage, GD2+, and responsive to anti-GD2 antibody therapy

K. O. McNerney et al.

Summary: This study demonstrates the utility of a mouse model of neuroblastoma to study immunotherapy approaches and investigate potential factors that determine adrenergic to mesenchymal fate decisions.

ONCOIMMUNOLOGY (2022)

Add to Collection
Article Oncology

Small extracellular vesicles induce resistance to anti-GD2 immunotherapy unveiling tipifarnib as an adjunct to neuroblastoma immunotherapy

Xiaoming Liu et al.

Summary: This study investigated the role of neuroblastoma-derived small extracellular vesicles (sEVs) in promoting resistance to anti-GD2 monoclonal antibody therapy and the potential of tipifarnib in sensitizing tumors to the antibody treatment. The results showed that sEVs attenuated the efficacy of the antibody and modulated the tumor microenvironment and immune cell infiltration. Additionally, tipifarnib enhanced the antibody's effectiveness against tumor growth and prevented the immunosuppressive effects of sEVs.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

Add to Collection
Article Oncology

Role of GD3 Synthase ST8Sia I in Cancers

Angelina Kasprowicz et al.

Summary: GD3 synthase is crucial for the biosynthesis of gangliosides, and targeting it can reduce malignant properties of tumors associated with gangliosides, such as migration, invasion, sternness, and epithelial-mesenchymal transition.

CANCERS (2022)

Add to Collection
Article Oncology

Epitope detection in monocytes (EDIM) for liquid biopsy including identification of GD2 in childhood neuroblastoma-a pilot study

Matias J. Stagno et al.

Summary: This study analyzed the role of epitope detection in monocytes (EDIM) technique for liquid biopsy in neuroblastoma (NB) patients. The results showed that the EDIM test could serve as a non-invasive tool for liquid biopsy in pediatric NB patients, aiding in risk stratification, tumor biology research, treatment monitoring, and early detection of tumor relapses.

BRITISH JOURNAL OF CANCER (2022)

Add to Collection
Article Oncology

Anti-GD2 Antibodies Conjugated to IL15 and IL21 Mediate Potent Antitumor Cytotoxicity against Neuroblastoma

Rosa Nguyen et al.

Summary: In this study, two new immunocytokines (IC) were developed by linking IL15 and IL21 to hu14.18 for the treatment of GD2-expressing neuroblastoma. Compared to hu14.18-IL2, hu14.18-IL15 and-IL21 showed better preclinical activity, warranting further consideration for clinical testing.

CLINICAL CANCER RESEARCH (2022)

Add to Collection
Article Immunology

A novel ganglioside-related risk signature can reveal the distinct immune landscape of neuroblastoma and predict the immunotherapeutic response

Jiaxing Yang et al.

Summary: This study elucidates the role of gangliosides in the prognosis and immune landscape of neuroblastoma, providing optimization strategies for chemotherapy and immunotherapy for this disease.

FRONTIERS IN IMMUNOLOGY (2022)

Add to Collection
Review Biochemistry & Molecular Biology

Gangliosides and Their Role in Multilineage Differentiation of Mesenchymal Stem Cells

Francesca Santilli et al.

Summary: This review critically analyzes the role of gangliosides in the differentiation of mesenchymal stem cells and examines their potential use as specific cell surface markers.

BIOMEDICINES (2022)

Add to Collection
Review Pharmacology & Pharmacy

Bispecific Antibodies in Cancer Immunotherapy: A Novel Response to an Old Question

Camila Ordonez-Reyes et al.

Summary: Immunotherapy, particularly bispecific antibodies, has revolutionized cancer treatment by redirecting the immune response towards specific antigens and tumor locations. This article discusses the design and function of bispecific antibodies, their challenges, and their current state-of-the-art in treating hematological and solid malignancies, as well as future perspectives.

PHARMACEUTICS (2022)

Add to Collection
Article Oncology

A randomised phase II trial of a trivalent ganglioside vaccine targeting GM2, GD2 and GD3 combined with immunological adjuvant OPT-821 versus OPT-821 alone in metastatic sarcoma patients rendered disease-free by surgery

Evan Rosenbaum et al.

Summary: This study aimed to control recurrence and improve outcomes in sarcoma patients after metastasectomy by administering a KLH-conjugated ganglioside vaccine and the immunological adjuvant OPT-821. Although vaccination induced a sustained serologic response, no differences were observed between treatment arms in terms of relapse-free survival and overall survival.

EUROPEAN JOURNAL OF CANCER (2022)

Add to Collection
Article Oncology

B3GALT4 remodels the tumor microenvironment through GD2-mediated lipid raft formation and the c-met/AKT/mTOR/IRF-1 axis in neuroblastoma

Yong-Liang Sha et al.

Summary: Upregulation of B3GALT4 promotes the recruitment of CD8(+) T lymphocytes by inducing the secretion of CXCL9 and CXCL10 via the GD2-mediated lipid rafts and the c-Met/AKT/mTOR/IRF-1 pathway in neuroblastoma (NB). Lipid raft inhibitors may enhance the efficacy of anti-GD2 immunotherapy for NB.

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2022)

Add to Collection
Review Oncology

Immunotherapies of retinoblastoma: Effective methods for preserving vision in the future

Ling Wang et al.

Summary: Retinoblastoma is the most common intraocular tumor in children. Chemotherapy is the main method of treatment currently, but immunotherapy has become a new strategy. This article summarizes several potential targets for retinoblastoma immunotherapy and discusses the corresponding techniques and feasibility.

FRONTIERS IN ONCOLOGY (2022)

Add to Collection
Article Oncology

Transition to a mesenchymal state in neuroblastoma confers resistance to anti-GD2 antibody via reduced expression of ST8SIA1

Nathaniel W. Mabe et al.

Summary: Mabe et al. found that the levels of GD2 are associated with lineage plasticity in neuroblastoma, and they identified ST8SIA1 as the critical enzyme in GD2 synthesis. Inhibition of EZH2 in mesenchymal neuroblastoma cells increases ST8SIA1 expression, synergizing with anti-GD2 antibodies. However, there is a lack of understanding about the mechanisms of resistance to anti-GD2 therapy. This study reveals that reduced GD2 expression is significantly correlated with the mesenchymal cell state in neuroblastoma, and a forced adrenergic-to-mesenchymal transition (AMT) leads to GD2 downregulation and resistance to anti-GD2 antibody. The pharmacologic inhibition of EZH2 results in epigenetic rewiring of mesenchymal neuroblastoma cells, enabling re-expression of ST8SIA1, restoration of GD2 surface expression, and sensitivity to anti-GD2 antibody.

NATURE CANCER (2022)

Add to Collection
Article Oncology

Therapeutic efficacy of antibody-drug conjugates targeting GD2-positive tumors

Daniel Kalinovsky et al.

Summary: This study is the first to analyze the cytotoxic activity of anti-GD2 antibody-drug conjugates (ADCs) against solid tumors. The ADCs showed cytotoxic effects in a wide panel of GD2-positive tumor cell lines and demonstrated antitumor effects in mouse models of GD2-positive solid cancer.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

Add to Collection
Review Biochemistry & Molecular Biology

Antibody drug conjugate: the biological missile for targeted cancer therapy

Zhiwen Fu et al.

Summary: Antibody-drug conjugates (ADCs) combine the highly specific targeting ability of monoclonal antibodies with the potent killing effect of cytotoxic drugs to accurately and efficiently eliminate cancer cells. Since the approval of the first ADC in 2000, 14 ADCs have been marketed worldwide, with over 100 ADC candidates currently in clinical trials. These novel cancer therapeutics, known as biological missiles, are leading the way in targeted cancer therapy.

SIGNAL TRANSDUCTION AND TARGETED THERAPY (2022)

Add to Collection
Article Oncology

ST8SIA1 inhibition sensitizes triple negative breast cancer to chemotherapy via suppressing Wnt/β-catenin and FAK/Akt/mTOR

H. Wan et al.

Summary: The study found that upregulation of ST8SIA1 is associated with chemoresistance in TNBC, and inhibition of ST8SIA1 can enhance the efficacy of chemotherapy by suppressing the FAK/Akt/mTOR and Wnt/beta-catenin signaling pathways.

CLINICAL & TRANSLATIONAL ONCOLOGY (2021)

Add to Collection
Article Oncology

Survival Impact of Anti-GD2 Antibody Response in a Phase II Ganglioside Vaccine Trial Among Patients With High-Risk Neuroblastoma With Prior Disease Progression

Irene Y. Cheung et al.

Summary: The study investigated the kinetics of antibody response to GD2/GD3 vaccine and beta-glucan in HR-NB patients, showing that higher anti-GD2-IgG1 titer was associated with improved survival.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection
Review Oncology

Tumor-Infiltrating Natural Killer Cells

Beatriz Cozar et al.

Summary: NK cells play a crucial role in immune responses to tumors by killing target cells and producing cytokines, but they can become dysfunctional in the immunosuppressive tumor microenvironment. This article provides an overview of NK tumor infiltration and surveillance, as well as the mechanisms by which NK cells become dysfunctional.

CANCER DISCOVERY (2021)

Add to Collection
Article Oncology

Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) plus Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032

Alice L. Yu et al.

Summary: The study showed that immuotherapy with dinutuximab improved outcomes for high-risk neuroblastoma patients. Although early termination for efficacy resulted in a smaller sample size, clinically significant long-term survival differences were observed.

CLINICAL CANCER RESEARCH (2021)

Add to Collection
Article Pharmacology & Pharmacy

Naxitamab: First Approval

Anthony Markham

Summary: Naxitamab is a humanised anti-GD2 monoclonal antibody developed for the treatment of neuroblastoma and other GD2-positive cancers, which has recently received accelerated approval from the US FDA. This antibody, in combination with a cell-stimulating factor, demonstrates therapeutic effects in patients with partial response, minor response, or stable disease.

DRUGS (2021)

Add to Collection
Article Oncology

GD2-specific chimeric antigen receptor-modified T cells targeting retinoblastoma - assessing tumor and T cell interaction

Jatuporn Sujjitjoon et al.

Summary: GD2-specific CAR T cells showed promising therapeutic potential against retinoblastoma by recognizing and effectively killing cells with high GD2 antigen expression in vitro. However, prolonged exposure to the tumor resulted in a diminished killing activity of GD2-CAR T cells, suggesting the potential benefit of combination therapy with immune checkpoint inhibitors.

TRANSLATIONAL ONCOLOGY (2021)

Add to Collection
Article Oncology

Exploiting Gangliosides for the Therapy of Ewing's Sarcoma and H3K27M-Mutant Diffuse Midline Glioma

Arthur Wingerter et al.

Summary: Osteosarcoma, Ewing's sarcoma, and H3K27M-mutant diffuse midline glioma are rare aggressive malignancies in children. Targeting and/or modulating tumor cell-specific GD2 may offer a new therapeutic strategy for these tumors. Dinutuximab may be effective in tumors with high GD2 expression, while disrupting ganglioside metabolism in H3K27M-mutant diffuse midline glioma could provide a new therapeutic option for this highly fatal cancer.

CANCERS (2021)

Add to Collection
Review Cell & Tissue Engineering

CAR-T cell therapy in T-cell malignancies: Is success a low-hanging fruit?

Pouya Safarzadeh Kozani et al.

Summary: CAR-T therapy has been successful in treating various types of relapsed/refractory B-cell malignancies, but faces challenges when combating T-cell malignancies, including fratricide, T-cell aplasia, and product contamination. Further research and improvements are needed to address these obstacles and enhance CAR-T therapy in T-cell malignancies.

STEM CELL RESEARCH & THERAPY (2021)

Add to Collection
Article Medicine, Research & Experimental

Knockdown of lncRNA MIR4435-2HG and ST8SIA1 expression inhibits the proliferation, invasion and migration of prostate cancer cells in vitro and in vivo by blocking the activation of the FAK/AKT/β-catenin signaling pathway

Pengyi Xing et al.

Summary: The study demonstrated that interference with MIR4435-2HG and ST8SIA1 could effectively inhibit the proliferation, invasion, and migration of prostate cancer cells by blocking the activation of the FAK/AKT/beta-catenin signaling pathway.

INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE (2021)

Add to Collection
Review Biochemistry & Molecular Biology

Application of the Antibody-Inducing Activity of Glycosphingolipids to Human Diseases

Tetsuya Okuda

Summary: Glycosphingolipids (GSLs), composed of oligosaccharides and ceramide, are important constituents of cell membranes and play crucial roles in immune responses. Variations in GSL structures among different cells can serve as cell identification markers and have potential pharmaceutical applications.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

Add to Collection
Article Oncology

Variable Expression of the Disialoganglioside GD2 in Breast Cancer Molecular Subtypes

Ramona Erber et al.

Summary: The study found that GD2 is expressed in more than 50% of breast cancer cases, with the highest frequency in hormone receptor-positive tumors. However, GD2 expression was not significantly associated with patient outcome.

CANCERS (2021)

Add to Collection
Article Biochemical Research Methods

Gangliosides of Human Glioblastoma Multiforme: A Comprehensive Mapping and Structural Analysis by Ion Mobility Tandem Mass Spectrometry

Mirela Sarbu et al.

Summary: GBM is a malignant and highly aggressive brain tumor with aberrant cell-surface glycosylation patterns in nearly all tumor cells. Profiling of ganglioside mixtures from GBM specimens revealed over 160 distinct components, dominated by GD3 and GT1 forms. The presence of GT1c(d18:1/24:1) was identified as a potential GBM marker for the first time using high performance ion mobility separation mass spectrometry.

JOURNAL OF THE AMERICAN SOCIETY FOR MASS SPECTROMETRY (2021)

Add to Collection
Article Oncology

Potent antitumor effect of T cells armed with anti-GD2 bispecific antibody

Miho Nakajima et al.

Summary: The study demonstrated potent cytotoxicity of T cells armed with hu3F8-BsAb against GD2(+) tumors in vitro and in vivo, with high cytotoxicity against melanoma and neuroblastoma xenografts in mice, along with T-cell infiltration and minimal side effects. This approach may have clinical utility for cytotherapy against human tumors in both adults and pediatrics.

PEDIATRIC BLOOD & CANCER (2021)

Add to Collection
Article Oncology

Potent ex vivo armed T cells using recombinant bispecific antibodies for adoptive immunotherapy with reduced cytokine release

Jeong A. Park et al.

Summary: T cell-based immunotherapies using BsAb armed T cells provide a safe alternative with improved antitumor potency. EATs release less TNF-alpha and infiltrate tumors faster, achieving robust antitumor responses. The in vivo potency of EAT therapy depends on BsAb dose, cell number, total dose, and treatment schedule intensity. EATs remain effective after cryopreservation, and third-party gamma delta -EATs offer an alternative for autologous T cell sources.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

Add to Collection
Article Oncology

Multiparametric flow cytometry highlights B7-H3 as a novel diagnostic/therapeutic target in GD2neg/low neuroblastoma variants

Alessandra Dondero et al.

Summary: This study used multiparametric flow cytometry to analyze the sensitivity of GD2 and B7-H3 surface expression in neuroblastoma patients, finding that MFC is highly sensitive and can rapidly and accurately assess bone marrow tumor burden, while also detecting GD2 low/negative neuroblastoma variants in relapsed patients.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

Add to Collection
Article Biochemistry & Molecular Biology

Ganglioside Composition Distinguishes Anaplastic Ganglioglioma Tumor Tissue from Peritumoral Brain Tissue: Complementary Mass Spectrometry and Thin-Layer Chromatography Evidence

Dragana Fabris et al.

Summary: Aberrations in ganglioside composition strongly correlate with tumor growth and invasiveness. Anaplastic ganglioglioma shows distinct ganglioside composition compared to peritumoral and healthy brain tissues, despite having lower total content. The specific ganglioside composition in anaplastic ganglioglioma demonstrates realistic expression patterns and corresponds to high-grade malignancy brain tumors.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

Add to Collection
Review Cell Biology

Comprehensive understanding of anchorage-independent survival and its implication in cancer metastasis

Zhong Deng et al.

Summary: Detachment is the critical step for cancer metastasis, exposing cells to different chemical and mechanical environments and multiple stresses. These stresses, including loss of growth stimuli and increased reactive oxygen species, have significant impacts on anchorage-independent survival and molecular signaling pathways, affecting cancer metastasis and treatment.

CELL DEATH & DISEASE (2021)

Add to Collection
Article Oncology

GD2-directed bispecific trifunctional antibody outperforms dinutuximab beta in a murine model for aggressive metastasized neuroblastoma

Felix Zirngibl et al.

Summary: EKTOMUN and SUREK demonstrated promising efficacy against neuroblastoma, activating effector cells and tumor-infiltrating T cells, and showing significant control over neuroblastoma metastases.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

Add to Collection
Article Cell Biology

Role of Sialyl-O-Acetyltransferase CASD1 on GD2 Ganglioside O-Acetylation in Breast Cancer Cells

Sumeyye Cavdarli et al.

Summary: Our study highlighted the key role of CASD1 in O-acetylation of GD2 in breast cancer cells, with results showing that CASD1 depletion reduced OAcGD2 expression while CASD1 overexpression increased OAcGD2 levels in SUM159PT cells. This emphasizes the need for further research on O-acetylation mechanisms.

CELLS (2021)

Add to Collection
Article Oncology

Dual-targeting CAR-T cells with optimal co-stimulation and metabolic fitness enhance antitumor activity and prevent escape in solid tumors

Koichi Hirabayashi et al.

Summary: The proposed CAR design enhances CAR-T cell metabolism and antitumor functions, showing rapid antitumor effects in vivo and preventing tumor escape, which is crucial for achieving clinical responses in patients.

NATURE CANCER (2021)

Add to Collection
Article Oncology

Surface expression of the immunotherapeutic target GD2 in osteosarcoma depends on cell confluency

Malena Wiebel et al.

Summary: The expression of G(D2) in osteosarcoma cell lines is highly variable and associated with increasing cell confluency in vitro, indicating that strategies for selective upregulation of GD2 are needed to effectively target this antigen in osteosarcoma.

CANCER REPORTS (2021)

Add to Collection
Article Oncology

The ganglioside GD2 as a circulating tumor biomarker for neuroblastoma

Frank Milton Balis et al.

PEDIATRIC BLOOD & CANCER (2020)

Add to Collection
Article Biotechnology & Applied Microbiology

Targeting GD2-positive glioblastoma by chimeric antigen receptor empowered mesenchymal progenitors

Giulia Golinelli et al.

CANCER GENE THERAPY (2020)

Add to Collection
Article Biochemistry & Molecular Biology

Profiling of O-acetylated Gangliosides Expressed in Neuroectoderm Derived Cells

Sumeyye Cavdarli et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)

Add to Collection
Review Biochemistry & Molecular Biology

Lipid rafts as signaling hubs in cancer cell survival/death and invasion: implications in tumor progression and therapy

Faustino Mollinedo et al.

JOURNAL OF LIPID RESEARCH (2020)

Add to Collection
Article Multidisciplinary Sciences

B4GALNT1 induces angiogenesis, anchorage independence growth and motility, and promotes tumorigenesis in melanoma by induction of ganglioside GM2/GD2

Hideki Yoshida et al.

SCIENTIFIC REPORTS (2020)

Add to Collection
Article Cell Biology

Diversity of Tumor-Infiltrating, γδ T-Cell Abundance in Solid Cancers

Ghita Chabab et al.

CELLS (2020)

Add to Collection
Review Oncology

Disialoganglioside GD2 Expression in Solid Tumors and Role as a Target for Cancer Therapy

Bassel Nazha et al.

FRONTIERS IN ONCOLOGY (2020)

Add to Collection
Article Biochemistry & Molecular Biology

RNA Sequencing-Based Identification of Ganglioside GD2-Positive Cancer Phenotype

Maxim Sorokin et al.

BIOMEDICINES (2020)

Add to Collection
Article Clinical Neurology

Periostin Is Expressed by Pericytes and Is Crucial for Angiogenesis in Glioma

Karin Huizer et al.

JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2020)

Add to Collection
Article Medicine, General & Internal

Association between Neu5Gc carbohydrate and serum antibodies against it provides the molecular link to cancer: French NutriNet-Sante study

Salam Bashir et al.

BMC MEDICINE (2020)

Add to Collection
Review Neurosciences

Gangliosides in the Brain: Physiology, Pathophysiology and Therapeutic Applications

Simonetta Sipione et al.

FRONTIERS IN NEUROSCIENCE (2020)

Add to Collection
Review Immunology

Aiming for the Sweet Spot: Glyco-Immune Checkpoints and γδ T Cells in Targeted Immunotherapy

Margarita Bartish et al.

FRONTIERS IN IMMUNOLOGY (2020)

Add to Collection
Article Oncology

GD2 or HER2 targeting T cell engaging bispecific antibodies to treat osteosarcoma

Jeong A. Park et al.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)

Add to Collection
Article Oncology

Co-Delivery of CPT-11 and Panobinostat with Anti-GD2 Antibody Conjugated Immunoliposomes for Targeted Combination Chemotherapy

Gils Jose et al.

CANCERS (2020)

Add to Collection
Review Cell Biology

Human and murine memory γδ T cells: Evidence for acquired immune memory in bacterial and viral infections and autoimmunity

Kevin Comeau et al.

CELLULAR IMMUNOLOGY (2020)

Add to Collection
Article Biotechnology & Applied Microbiology

EZH2 Inhibition in Ewing Sarcoma Upregulates GD2 Expression for Targeting with Gene-Modified T Cells

Sareetha Kailayangiri et al.

MOLECULAR THERAPY (2019)

Add to Collection
Review Biochemistry & Molecular Biology

Developmental origins and emerging therapeutic opportunities for childhood cancer

Mariella Filbin et al.

NATURE MEDICINE (2019)

Add to Collection
Meeting Abstract Oncology

Phase I study of OKT3 x hu3F8 bispecific antibody (GD2Bi) armed T cells (GD2BATs) in GD2-positive tumors.

Maxim Yankelevich et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

Add to Collection
Article Multidisciplinary Sciences

A NOTCH feed-forward loop drives reprogramming from adrenergic to mesenchymal state in neuroblastoma

Tim van Groningen et al.

NATURE COMMUNICATIONS (2019)

Add to Collection
Article Oncology

NKT Cells Coexpressing a GD2-Specific Chimeric Antigen Receptor and IL15 Show Enhanced In Vivo Persistence and Antitumor Activity against Neuroblastoma

Xin Xu et al.

CLINICAL CANCER RESEARCH (2019)

Add to Collection
Review Pharmacology & Pharmacy

An update on emerging drugs in osteosarcoma: towards tailored therapies?

Claudia Maria Hattinger et al.

EXPERT OPINION ON EMERGING DRUGS (2019)

Add to Collection
Article Biochemistry & Molecular Biology

Combined sialic acid and histone deacetylase (HDAC) inhibitor treatment up-regulates the neuroblastoma antigen GD2

Renske J. E. van den Bijgaart et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2019)

Add to Collection
Article Multidisciplinary Sciences

Induction of specific adaptive immune responses by immunization with newly designed artificial glycosphingolipids

Tetsuya Okuda et al.

SCIENTIFIC REPORTS (2019)

Add to Collection
Article Pathology

Expression of Disialoganglioside (GD2) in Neuroblastic Tumors: A Prognostic Value for Patients Treated With Anti-GD2 Immunotherapy

Tatjana Terzic et al.

PEDIATRIC AND DEVELOPMENTAL PATHOLOGY (2018)

Add to Collection
Article Oncology

A phase II study of radioimmunotherapy with intraventricular 131I-3F8 for medulloblastoma

Kim Kramer et al.

PEDIATRIC BLOOD & CANCER (2018)

Add to Collection
Article Biochemistry & Molecular Biology

Human Neuraminidase lsoenzymes Show Variable Activities for 9-O-Acetyl-sialoside Substrates

Carmanah D. Hunter et al.

ACS CHEMICAL BIOLOGY (2018)

Add to Collection
Review Biochemistry & Molecular Biology

Emerging concepts of ganglioside metabolism

Roger Sandhoff et al.

FEBS LETTERS (2018)

Add to Collection
Article Oncology

Enhancement of malignant properties of human glioma cells by ganglioside GD3/GD2

Taiji Iwasawa et al.

INTERNATIONAL JOURNAL OF ONCOLOGY (2018)

Add to Collection
Article Biotechnology & Applied Microbiology

Chimeric Antigen Receptor-Engineered Human Gamma Delta T Cells: Enhanced Cytotoxicity with Retention of Cross Presentation

Anna Capsomidis et al.

MOLECULAR THERAPY (2018)

Add to Collection
Review Oncology

GM3(Neu5Gc) ganglioside: an evolution fixed neoantigen for cancer immunotherapy

Mayrel Labrada et al.

SEMINARS IN ONCOLOGY (2018)

Add to Collection
Review Cell & Tissue Engineering

Cancer Stem Cells (CSCs) in Drug Resistance and their Therapeutic Implications in Cancer Treatment

Lan Thi Hanh Phi et al.

STEM CELLS INTERNATIONAL (2018)

Add to Collection
Review Immunology

Interferon-Gamma at the Crossroads of Tumor Immune Surveillance or Evasion

Flavia Castro et al.

FRONTIERS IN IMMUNOLOGY (2018)

Add to Collection
Article Oncology

PHLDA1, another PHLDA family protein that inhibits Akt

Yu Chen et al.

CANCER SCIENCE (2018)

Add to Collection
Review Medicine, Research & Experimental

Unleashing endogenous TNF-alpha as a cancer immunotherapeutic

Steven F. Josephs et al.

JOURNAL OF TRANSLATIONAL MEDICINE (2018)

Add to Collection
Article Oncology

ST8SIA1 Regulates Tumor Growth and Metastasis in TNBC by Activating the FAK-AKT-mTOR Signaling Pathway

Khoa Nguyen et al.

MOLECULAR CANCER THERAPEUTICS (2018)

Add to Collection
Article Biochemical Research Methods

A validated HPLC-MS/MS method for estimating the concentration of the ganglioside, G(D2), in human plasma or serum

C. M. Busch et al.

JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2018)

Add to Collection
Article Oncology

Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial

Ruth Ladenstein et al.

LANCET ONCOLOGY (2018)

Add to Collection
Article Oncology

Humanized 3F8 Anti-G(D2) Monoclonal Antibody Dosing With Granulocyte-Macrophage Colony-Stimulating Factor in Patients With Resistant Neuroblastoma A Phase 1 Clinical Trial

Brian H. Kushner et al.

JAMA ONCOLOGY (2018)

Add to Collection
Review Biochemistry & Molecular Biology

Epigenetic regulation of ganglioside expression in neural stem cells and neuronal cells

Yutaka Itokazu et al.

GLYCOCONJUGATE JOURNAL (2017)

Add to Collection
Article Oncology

Lack of immunocytological GD2 expression on neuroblastoma cells in bone marrow at diagnosis, during treatment, and at recurrence

Roswitha Schumacher-Kuckelkorn et al.

PEDIATRIC BLOOD & CANCER (2017)

Add to Collection
Article Biotechnology & Applied Microbiology

CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma

Andras Heczey et al.

MOLECULAR THERAPY (2017)

Add to Collection
Article Genetics & Heredity

Neuroblastoma is composed of two super-enhancer-associated differentiation states

Tim van Groningen et al.

NATURE GENETICS (2017)

Add to Collection
Article Genetics & Heredity

Heterogeneity of neuroblastoma cell identity defined by transcriptional circuitries

Valentina Boeva et al.

NATURE GENETICS (2017)

Add to Collection
Article Oncology

Targeting tumor-associated carbohydrate antigens: a phase I study of a carbohydrate mimetic-peptide vaccine in stage IV breast cancer subjects

Laura F. Hutchins et al.

ONCOTARGET (2017)

Add to Collection
Article Oncology

Expression of ganglioside GD2, reprogram the lipid metabolism and EMT phenotype in bladder cancer

Venkatrao Vantaku et al.

ONCOTARGET (2017)

Add to Collection
Review Immunology

Targeting O-Acetyl-GD2 Ganglioside for Cancer Immunotherapy

Julien Fleurence et al.

JOURNAL OF IMMUNOLOGY RESEARCH (2017)

Add to Collection
Review Oncology

Double-edged sword of mesenchymal stem cells: Cancer-promoting versus therapeutic potential

Hwa-Yong Lee et al.

CANCER SCIENCE (2017)

Add to Collection
Article Biochemistry & Molecular Biology

Ceramide synthases in biomedical research

Francesca Cingolani et al.

CHEMISTRY AND PHYSICS OF LIPIDS (2016)

Add to Collection
Review Immunology

Immunocytokines for cancer treatment: past, present and future

Dario Neri et al.

CURRENT OPINION IN IMMUNOLOGY (2016)

Add to Collection
Review Immunology

Anti-GD2 mAbs and next-generation mAb-based agents for cancer therapy

Zulmarie Perez Horta et al.

IMMUNOTHERAPY (2016)

Add to Collection
Article Oncology

Oncotargets GD2 and GD3 are highly expressed in sarcomas of children, adolescents, and young adults

Konstantin Dobrenkov et al.

PEDIATRIC BLOOD & CANCER (2016)

Add to Collection
Review Pharmacology & Pharmacy

Cancer stem cells and chemoresistance: The smartest survives the raid

Jihe Zhao

PHARMACOLOGY & THERAPEUTICS (2016)

Add to Collection
Article Multidisciplinary Sciences

Preparation of CD4+ T Cells for Analysis of GD3 and GD2 Ganglioside Membrane Expression by Microscopy

Tania M. Villanueva-Cabello et al.

JOVE-JOURNAL OF VISUALIZED EXPERIMENTS (2016)

Add to Collection
Article Oncology

Anti-GD2 mAb and Vorinostat synergize in the treatment of neuroblastoma

Michiel Kroesen et al.

ONCOIMMUNOLOGY (2016)

Add to Collection
Article Oncology

Successful engineering of a highly potent single-chain variable-fragment (scFv) bispecific antibody to target disialoganglioside (GD2) positive tumors

Ming Cheng et al.

ONCOIMMUNOLOGY (2016)

Add to Collection
Article Multidisciplinary Sciences

Generation and Characterization of a Human/Mouse Chimeric GD2-Mimicking Anti-Idiotype Antibody Ganglidiximab for Active Immunotherapy against Neuroblastoma

Christin Eger et al.

PLOS ONE (2016)

Add to Collection
Article Multidisciplinary Sciences

Ganglioside Profiling of the Human Retina: Comparison with Other Ocular Structures, Brain and Plasma Reveals Tissue Specificities

Estelle Sibille et al.

PLOS ONE (2016)

Add to Collection
Article Biochemistry & Molecular Biology

Analysis of genes involved in response to doxorubicin and a GD2 ganglioside-specific 14G2a monoclonal antibody in IMR-32 human neuroblastoma cells

Irena Horwacik et al.

ACTA BIOCHIMICA POLONICA (2015)

Add to Collection
Article Biochemistry & Molecular Biology

Activation of human naive Th cells increases surface expression of GD3 and induces neoexpression of GD2 that colocalize with TCR clusters

Tania M. Villanueva-Cabello et al.

GLYCOBIOLOGY (2015)

Add to Collection
Article Oncology

Multifaceted roles of 5′-regulatory region of the cancer associated gene B4GALT1 and its comparison with the gene family

Mohammed A. Ibrahim Al-Obaide et al.

INTERNATIONAL JOURNAL OF ONCOLOGY (2015)

Add to Collection
Article Multidisciplinary Sciences

Ligands Binding to Cell Surface Ganglioside GD2 Cause Src-Dependent Activation of N-Methyl-D-Aspartate Receptor Signaling and Changes in Cellular Morphology

Wenyong Tong et al.

PLOS ONE (2015)

Add to Collection
Article Multidisciplinary Sciences

9-O-Acetylation of sialic acids is catalysed by CASD1 via a covalent acetyl-enzyme intermediate

Anna-Maria T. Baumann et al.

NATURE COMMUNICATIONS (2015)

Add to Collection
Article Oncology

Anti-proliferative and pro-apoptotic activity of GD2 ganglioside-specific monoclonal antibody 3F8 in human melanoma cells

Chun-Yen Tsao et al.

ONCOIMMUNOLOGY (2015)

Add to Collection
Article Oncology

Structural design of disialoganglioside GD2 and CD3-bispecific antibodies to redirect T cells for tumor therapy

Ming Cheng et al.

INTERNATIONAL JOURNAL OF CANCER (2015)

Add to Collection
Article Oncology

Comparison of Pain Outcomes Between Two Anti-GD2 Antibodies in Patients With Neuroblastoma

Doralina L. Anghelescu et al.

PEDIATRIC BLOOD & CANCER (2015)

Add to Collection
Article Oncology

Retargeting T Cells to GD2 Pentasaccharide on Human Tumors Using Bispecific Humanized Antibody

Hong Xu et al.

CANCER IMMUNOLOGY RESEARCH (2015)

Add to Collection
Article Oncology

Ganglioside GD2 expression is maintained upon recurrence in patients with osteosarcoma

Vincent I. Poon et al.

CLINICAL SARCOMA RESEARCH (2015)

Add to Collection
Article Hematology

Invariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy

Andras Heczey et al.

BLOOD (2014)

Add to Collection
Article Oncology

Ganglioside GD2 as a Therapeutic Target for Antibody-Mediated Therapy in Patients With Osteosarcoma

Michael Roth et al.

CANCER (2014)

Add to Collection
Article Oncology

Phase I Trial of a Bivalent Gangliosides Vaccine in Combination with β-Glucan for High-Risk Neuroblastoma in Second or Later Remission

Brian H. Kushner et al.

CLINICAL CANCER RESEARCH (2014)

Add to Collection
Article Biochemistry & Molecular Biology

Epigenetic activation of mouse ganglioside synthase genes: implications for neurogenesis

Yi-Tzang Tsai et al.

JOURNAL OF NEUROCHEMISTRY (2014)

Add to Collection
Article Multidisciplinary Sciences

Chimeric Antibody c. 8B6 to O-Acetyl-GD2 Mediates the Same Efficient Anti-Neuroblastoma Effects as Therapeutic ch14.18 Antibody to GD2 without Antibody Induced Allodynia

Mickael Terme et al.

PLOS ONE (2014)

Add to Collection
Article Multidisciplinary Sciences

Endothelin A Receptor Antagonism Enhances Inhibitory Effects of Anti-Ganglioside GD2 Monoclonal Antibody on Invasiveness and Viability of Human Osteosarcoma Cells

Bo Liu et al.

PLOS ONE (2014)

Add to Collection
Article Oncology

Vaccination with anti-idiotype antibody ganglidiomab mediates a GD2-specific anti-neuroblastoma immune response

Holger N. Lode et al.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2013)

Add to Collection
Article Oncology

Cell cycle arrest and apoptosis induced by O-acetyl-GD2-specific monoclonal antibody 8B6 inhibits tumor growth in vitro and in vivo

Denis Cochonneau et al.

CANCER LETTERS (2013)

Add to Collection
Article Oncology

Targeting GD2 ganglioside and aurora A kinase as a dual strategy leading to cell death in cultures of human neuroblastoma cells

Irena Horwacik et al.

CANCER LETTERS (2013)

Add to Collection
Article Oncology

Tumor targeting of the IL-15 superagonist RLI by an anti-GD2 antibody strongly enhances its antitumor potency

Marie Vincent et al.

INTERNATIONAL JOURNAL OF CANCER (2013)

Add to Collection
Article Genetics & Heredity

Fenretinide sensitizes multidrug-resistant human neuroblastoma cells to antibody-independent and ch14.18-mediated NK cell cytotoxicity

Anastasia Shibina et al.

JOURNAL OF MOLECULAR MEDICINE-JMM (2013)

Add to Collection
Article Multidisciplinary Sciences

In silico Driven Redesign of a Clinically Relevant Antibody for the Treatment of GD2 Positive Tumors

Mahiuddin Ahmed et al.

PLOS ONE (2013)

Add to Collection
Article Multidisciplinary Sciences

Differential expression profiles of glycosphingolipids in human breast cancer stem cells vs. cancer non-stem cells

Yuh-Jin Liang et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)

Add to Collection
Review Oncology

Mechanisms of chemoresistance in cancer stem cells

Lissa Nurrul Abdullah et al.

CLINICAL AND TRANSLATIONAL MEDICINE (2013)

Add to Collection
Article Oncology

Enhancement of malignant properties of human osteosarcoma cells with disialyl gangliosides GD2/GD3

Hidenobu Shibuya et al.

CANCER SCIENCE (2012)

Add to Collection
Article Cell Biology

Lipid Sorting by Ceramide Structure from Plasma Membrane to ER for the Cholera Toxin Receptor Ganglioside GM1

Daniel J-F. Chinnapen et al.

DEVELOPMENTAL CELL (2012)

Add to Collection
Article Biochemistry & Molecular Biology

The ganglioside GD2 induces the constitutive activation of c-Met in MDA-MB-231 breast cancer cells expressing the GD3 synthase

Aurelie Cazet et al.

GLYCOBIOLOGY (2012)

Add to Collection
Article Biochemistry & Molecular Biology

Disialyl gangliosides enhance tumor phenotypes with differential modalities

Koichi Furukawa et al.

GLYCOCONJUGATE JOURNAL (2012)

Add to Collection
Article Medicine, Research & Experimental

Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment

Nidale Tarek et al.

JOURNAL OF CLINICAL INVESTIGATION (2012)

Add to Collection
Article Medicine, Research & Experimental

Ganglioside GD2 identifies breast cancer stem cells and promotes tumorigenesis

Venkata Lokesh Battula et al.

JOURNAL OF CLINICAL INVESTIGATION (2012)

Add to Collection
Article Oncology

Activation of Peripheral-Blood Granulocytes Is Strongly Correlated With Patient Outcome After Immunotherapy With Anti-GD2 Monoclonal Antibody and Granulocyte-Macrophage Colony-Stimulating Factor

Irene Y. Cheung et al.

JOURNAL OF CLINICAL ONCOLOGY (2012)

Add to Collection
Review Biochemistry & Molecular Biology

Dihydroceramide desaturase and dihydrosphingolipids: Debutant players in the sphingolipid arena

Gemma Fabrias et al.

PROGRESS IN LIPID RESEARCH (2012)

Add to Collection
Article Oncology

Humanizing murine IgG3 anti-GD2 antibody m3F8 substantially improves antibody-dependent cell-mediated cytotoxicity while retaining targeting in vivo

Nai-Kong V. Cheung et al.

ONCOIMMUNOLOGY (2012)

Add to Collection
Article Biochemistry & Molecular Biology

Molecular Microscopy of Brain Gangliosides: Illustrating their Distribution in Hippocampal Cell Layers

Benoit Colsch et al.

ACS CHEMICAL NEUROSCIENCE (2011)

Add to Collection
Review Biochemistry & Molecular Biology

Mechanistic enzymology of serine palmitoyltransferase

Hiroko Ikushiro et al.

BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS (2011)

Add to Collection
Article Hematology

Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma

Chrystal U. Louis et al.

BLOOD (2011)

Add to Collection
Article Oncology

Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapy

Thorsten Simon et al.

BMC CANCER (2011)

Add to Collection
Review Chemistry, Multidisciplinary

Sphingolipid and Glycosphingolipid Metabolic Pathways in the Era of Sphingolipidomics

Alfred H. Merrill

CHEMICAL REVIEWS (2011)

Add to Collection
Article Biochemistry & Molecular Biology

The human Cas1 protein: A sialic acid-specific O-acetyltransferase?

Sigrid Arming et al.

GLYCOBIOLOGY (2011)

Add to Collection
Article Oncology

Successful Multifold Dose Escalation of Anti-GD2 Monoclonal Antibody 3F8 in Patients With Neuroblastoma: A Phase I Study

Brian H. Kushner et al.

JOURNAL OF CLINICAL ONCOLOGY (2011)

Add to Collection
Review Immunology

NK Cells and Immune Memory

Joseph C. Sun et al.

JOURNAL OF IMMUNOLOGY (2011)

Add to Collection
Article Cell Biology

Differential internalization of hu14.18-IL2 immunocytokine by NK and tumor cell: impact on conjugation, cytotoxicity, and targeting

Ilia N. Buhtoiarov et al.

JOURNAL OF LEUKOCYTE BIOLOGY (2011)

Add to Collection
Article Biotechnology & Applied Microbiology

Selective Therapeutic Targeting of the Anaplastic Lymphoma Kinase With Liposomal siRNA Induces Apoptosis and Inhibits Angiogenesis in Neuroblastoma

Daniela Di Paolo et al.

MOLECULAR THERAPY (2011)

Add to Collection
Article Multidisciplinary Sciences

A Monoclonal Antibody to O-Acetyl-GD2 Ganglioside and Not to GD2 Shows Potent Anti-Tumor Activity without Peripheral Nervous System Cross-Reactivity

Nidia Alvarez-Rueda et al.

PLOS ONE (2011)

Add to Collection
Article Oncology

Anti-Neuroblastoma Activity of Gold Nanorods Bound with GD2 Monoclonal Antibody under Near-Infrared Laser Irradiation

Ching-An Peng et al.

Cancers (2011)

Add to Collection
Review Biochemistry & Molecular Biology

Fatty acid 2-Hydroxylation in mammalian sphingolipid biology

Hiroko Hama

BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS (2010)

Add to Collection
Article Oncology

Genotypes of NK Cell KIR Receptors, Their Ligands, and Fcγ Receptors in the Response of Neuroblastoma Patients to Hu14.18-IL2 Immunotherapy

David C. Delgado et al.

CANCER RESEARCH (2010)

Add to Collection
Review Biochemistry & Molecular Biology

Altered sphingolipid metabolism induced by tumor hypoxia - New vistas in glycolipid tumor markers

Jun Yin et al.

FEBS LETTERS (2010)

Add to Collection
Article Biochemistry & Molecular Biology

Separation and identification of GM1b pathway Neu5Ac-and Neu5Gc gangliosides by on-line nanoHPLC-QToF MS and tandem MS: toward glycolipidomics screening of animal cell lines

Mostafa Zarei et al.

GLYCOBIOLOGY (2010)

Add to Collection
Article Oncology

Shedding of GD2 ganglioside in patients with retinoblastoma

Jacques Portoukalian et al.

INTERNATIONAL JOURNAL OF CANCER (2010)

Add to Collection
Article Oncology

Antitumor Activity of Hu14.18-IL2 in Patients With Relapsed/Refractory Neuroblastoma: A Children's Oncology Group (COG) Phase II Study

Suzanne Shusterman et al.

JOURNAL OF CLINICAL ONCOLOGY (2010)

Add to Collection
Letter Oncology

14G2a Anti-GD2 Crossreactivity With the CD166 Antigen

Vaidehi Agrawal et al.

JOURNAL OF IMMUNOTHERAPY (2010)

Add to Collection
Article Medicine, General & Internal

Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma.

Alice L. Yu et al.

NEW ENGLAND JOURNAL OF MEDICINE (2010)

Add to Collection
Article Anesthesiology

Anti-GD(2) with an FC point mutation reduces complement fixation and decreases antibody-induced allodynia

Linda S. Sorkin et al.

PAIN (2010)

Add to Collection
Review Biochemistry & Molecular Biology

CERT-mediated trafficking of ceramide

Kentaro Hanada et al.

BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS (2009)

Add to Collection
Article Oncology

The GD2-specific 14G2a monoclonal antibody induces apoptosis and enhances cytotoxicity of chemotherapeutic drugs in IMR-32 human neuroblastoma cells

Aleksandra Kowalczyk et al.

CANCER LETTERS (2009)

Add to Collection
Article Physics, Atomic, Molecular & Chemical

High-throughput analysis of gangliosides in defined regions of fetal brain by fully automated chip-based nanoelectrospray ionization multi-stage mass spectrometry

Alina Serb et al.

EUROPEAN JOURNAL OF MASS SPECTROMETRY (2009)

Add to Collection
Article Biochemistry & Molecular Biology

Multiple changes in sialic acid biology during human evolution

Ajit Varki

GLYCOCONJUGATE JOURNAL (2009)

Add to Collection
Article Multidisciplinary Sciences

Sensitive and Specific Detection of the Non-Human Sialic Acid N-Glycolylneuraminic Acid In Human Tissues and Biotherapeutic Products

Sandra L. Diaz et al.

PLOS ONE (2009)

Add to Collection
Article Oncology

Detection of GD2-positive cells in bone marrow samples and survival of patients with localised neuroblastoma

M. V. Corrias et al.

BRITISH JOURNAL OF CANCER (2008)

Add to Collection
Article Cell Biology

Inhibitory role of focal adhesion kinase on anoikis in the lung cancer cell A549

Gaiyun Liu et al.

CELL BIOLOGY INTERNATIONAL (2008)

Add to Collection
Review Cell & Tissue Engineering

The (in) auspicious role of mesenchymal stromal cells in cancer: be it friend or foe

S. Kidd et al.

CYTOTHERAPY (2008)

Add to Collection
Review Biochemistry & Molecular Biology

Thematic review series: Sphingolipids - Biodiversity of sphingoid bases (sphingosines) and related amino alcohols

Sarah T. Pruett et al.

JOURNAL OF LIPID RESEARCH (2008)

Add to Collection
Article Multidisciplinary Sciences

Evidence for a human-specific mechanism for diet and antibody-mediated inflammation in carcinoma progression

Maria Hedlund et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)

Add to Collection
Article Hematology

Human bone marrow mesenchymal stromal cells express the neural ganglioside GD2: a novel surface marker for the identification of MSCs

Caridad Martinez et al.

BLOOD (2007)

Add to Collection
Article Oncology

FDA approval summary: Vorinostat for treatment of advanced primary cutaneous T-cell lymphoma

Bhupinder S. Mann et al.

ONCOLOGIST (2007)

Add to Collection
Article Oncology

Characterization of GD2 peptide mimotope DNA Vaccines effective against spontaneous neuroblastoma metastases

Stefan Fest et al.

CANCER RESEARCH (2006)

Add to Collection
Article Cell Biology

Integrin-regulated FAK-Src signaling in normal and cancer cells

Satyajit K. Mitra et al.

CURRENT OPINION IN CELL BIOLOGY (2006)

Add to Collection
Article Immunology

Induction of IgG antibodies against the GD2 carbohydrate tumor antigen by vaccination with peptide mimotopes

Angelika B. Riemer et al.

EUROPEAN JOURNAL OF IMMUNOLOGY (2006)

Add to Collection
Article Biochemistry & Molecular Biology

Mechanisms for the apoptosis of small cell lung cancer cells induced by anti-GD2 monoclonal antibodies - Roles of anoikis

W Aixinjueluo et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2005)

Add to Collection
Article Oncology

DNA vaccine expressing the mimotope of GD2 ganglioside induces protective GD2 cross-reactive antibody responses

E Bolesta et al.

CANCER RESEARCH (2005)

Add to Collection
Article Biochemistry & Molecular Biology

Isolation and structural analysis of peptide mimotopes for the disialoganglioside GD2, a neuroblastoma tumor antigen

E Föster-Waldl et al.

MOLECULAR IMMUNOLOGY (2005)

Add to Collection
Article Surgery

Focal adhesion kinase gene silencing promotes anoikis and suppresses metastasis of human pancreatic adenocarcinoma cells

MS Duxbury et al.

SURGERY (2004)

Add to Collection
Article Oncology

Consolidation treatment with chimeric anti-GD2-antibody ch14.18 in children older than 1 year with metastatic neuroblastoma

T Simon et al.

JOURNAL OF CLINICAL ONCOLOGY (2004)

Add to Collection
Article Biochemistry & Molecular Biology

Isolation and functional analysis of the melanoma specific promoter region of human GD3 synthase gene

K Furukawa et al.

BIOCHIMICA ET BIOPHYSICA ACTA-GENE STRUCTURE AND EXPRESSION (2003)

Add to Collection
Article Oncology

Quantitation of GD2 synthase mRNA by real-time reverse transcriptase polymerase chain reaction: Clinical utility in evaluating adjuvant therapy in neuroblastoma

IY Cheung et al.

JOURNAL OF CLINICAL ONCOLOGY (2003)

Add to Collection
Review Biochemistry & Molecular Biology

Salvage pathways in glycosphingolipid metabolism

G Tettamanti et al.

BIOCHIMIE (2003)

Add to Collection
Article Biochemistry & Molecular Biology

Regulation of ganglioside biosynthesis by enzyme complex formation of glycosyltransferases

E Bieberich et al.

BIOCHEMISTRY (2002)

Add to Collection
Article Oncology

An anti-GD2 monoclonal antibody enhances apoptotic effects of anti-cancer drugs against small cell lung cancer cells via JNK (c-jun terminal kinase) activation

S Yoshida et al.

JAPANESE JOURNAL OF CANCER RESEARCH (2002)

Add to Collection
Article Oncology

Follow-up in neuroblastoma:: Comparison of metaiodobenzylguanidine and a chimeric anti-GD2 antibody for detection of tumor relapse and therapy response

P Reuland et al.

JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY (2001)

Add to Collection
Article Pathology

Ganglioside GM2/GD2 synthetase mRNA is a marker for detection of infrequent neuroblastoma cells in bone marrow

DSB Hoon et al.

AMERICAN JOURNAL OF PATHOLOGY (2001)

Add to Collection
Article Oncology

Phase I study of chimeric human/murine anti-ganglioside GD2 monoclonal antibody (ch14.18) with granulocyte-macrophage colony-stimulating factor in children with neuroblastoma immediately after hematopoietic stem-cell transplantation:: A Children's Cancer Group Study

MF Ozkaynak et al.

JOURNAL OF CLINICAL ONCOLOGY (2000)

Add to Collection
Article Biochemistry & Molecular Biology

Effect of N-glycosylation on turnover and subcellular distribution of N-acetylgalactosaminyltransferase I and sialyltransferase II in neuroblastoma cells

E Bieberich et al.

JOURNAL OF NEUROCHEMISTRY (2000)

Add to Collection
Article Oncology

Clinical and immune responses in advanced melanoma patients immunized with an anti-idiotype antibody mimicking disialoganglioside GD2

KA Foon et al.

JOURNAL OF CLINICAL ONCOLOGY (2000)

Add to Collection
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.